Growth Hormone for the Treatment of Gastroparesis

Overview

About this study

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Symptoms > 6 months that have not responded satisfactorily to standard treatment.
  • For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of > 21

Exclusion Criteria: 

  • Known history of GH deficiency, hypothalamic or pituitary disease.
  • Diabetes.
  • Prior use of GH therapy.
  • Age-adjusted low serum IGF1.
  • Women on oral estrogen therapy6.
  • Pregnancy or nursing.
  • History of coronary and thromboembolic diseases.
  • History of thyroid nodules.
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
  • Failure to give informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/20/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tisha Lunsford, M.D.

Open for enrollment

Contact information:

Guillermo Barahona Hernandez

(480) 301-4679

Barahona.Guillermo@mayo.edu

More information

Publications

Publications are currently not available